Effect of High Carbohydrate vs. Low Carbohydrate Diet in Type 2 Diabetes
Role of Hepatic Glycogen on Nocturnal EGP in T2D
2 other identifiers
interventional
34
1 country
1
Brief Summary
The experimental approach in this study intends to investigate the role of hepatic glycogen content on nocturnal regulation of endogenous glucose production including the relative contributions of glycogenolysis and gluconeogenesis and the extent to which this differs between subjects with type 2 diabetes and subjects without diabetes. Both participants with type 2 diabetes and participants without diabetes will be studied after consuming either a low carbohydrate (no glycogen loading) or high carbohydrate (glycogen loading) diet.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at below P25 for not_applicable diabetes-mellitus
Started Aug 2020
Typical duration for not_applicable diabetes-mellitus
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
First Submitted
Initial submission to the registry
June 1, 2020
CompletedFirst Posted
Study publicly available on registry
June 4, 2020
CompletedStudy Start
First participant enrolled
August 21, 2020
CompletedPrimary Completion
Last participant's last visit for primary outcome
August 15, 2022
CompletedStudy Completion
Last participant's last visit for all outcomes
February 15, 2023
CompletedResults Posted
Study results publicly available
December 18, 2023
CompletedMarch 1, 2024
February 1, 2024
2 years
June 1, 2020
September 27, 2023
February 28, 2024
Conditions
Keywords
Outcome Measures
Primary Outcomes (1)
Hepatic Glycogen Content and Rates of Gluconeogenesis in Subjects With Type 2 Diabetes
We measured the rates and contribution of Gluconeogenesis (GNG) to nocturnal Endogenous Glucose Production (EGP) using the deuterated water technique after either glycogen loading or no glycogen loading in subjects with type 2 diabetes.
Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks
Secondary Outcomes (2)
Rates of Glycogenolysis in Subjects With Type 2 Diabetes
Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks
Rates of Gluconeogenesis in Healthy Subjects
Subjects will complete both glycogen loading and no glycogen loading visits within approximately 6 weeks
Study Arms (2)
Type 2 diabetes
EXPERIMENTALParticipants with Type 2 Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
Participants without diabetes
EXPERIMENTALParticipants with no Diabetes received Glycogen loading (GL) and Non-Glycogen loading (NGL) meal in a randomized manner.
Interventions
Subjects will consume an isocaloric diet \[60% carbs, 20% protein, 20% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
Subjects will consume an isocaloric diet \[40% carbs, 20% protein, 40% fat (33 kcal/kg/day)\] for 3 days prior to the overnight study.
Eligibility Criteria
You may qualify if:
- Age 30-75
- BMI 20-35kg/m\^2
- Participants with type 2 diabetes:
- HbA1c less than or equal to 8.5% on lifestyle therapy or monotherapy with metformin or sulphonylureas (SU); or less than or equal to 7.5% on two oral hypoglycemic agents (Metformin and SU)
You may not qualify if:
- Pregnancy or breast feeding
- Morbidities precluding participation
- Participants with type 2 diabetes:
- Therapy with insulin
- SGLT2 inhibitors
- GLP-1 based approaches
- TZDs
- Unstable diabetic retinopathy
- Microalbuminuria
- Macrovascular disease
- Medications affecting GI motility (eg., erythromycin, pramlintide)
- Upper GI disorder/surgery
- Participants without diabetes:
- Medications (except stable thyroid hormone or hormone replacement therapy) that could influence glucose tolerance
- History of diabetes mellitus in first degree family members or prior history of diabetes mellitus or gestational diabetes, or pre-diabetes
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
University of Virginia
Charlottesville, Virginia, 22908, United States
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Limitations and Caveats
• Though unlikely, it is possible that additional steps to load hepatic glycogen maybe necessary (e.g., late night snack: high carb in GL and isocaloric low carb in NGL) to maximize differences in liver glycogen contents between visits.
Results Point of Contact
- Title
- Dr. Rita Basu
- Organization
- University of Alabama at Birmingham
Publication Agreements
- PI is Sponsor Employee
- No
- Restrictive Agreement
- No
Study Design
- Study Type
- interventional
- Phase
- not applicable
- Allocation
- RANDOMIZED
- Masking
- NONE
- Masking Details
- A total of 34 subjects participated.
- Purpose
- BASIC SCIENCE
- Intervention Model
- CROSSOVER
- Sponsor Type
- OTHER
- Responsible Party
- PRINCIPAL INVESTIGATOR
- PI Title
- Principal Investigator
Study Record Dates
First Submitted
June 1, 2020
First Posted
June 4, 2020
Study Start
August 21, 2020
Primary Completion
August 15, 2022
Study Completion
February 15, 2023
Last Updated
March 1, 2024
Results First Posted
December 18, 2023
Record last verified: 2024-02
Data Sharing
- IPD Sharing
- Will not share